Advertisement
U.S. markets closed

iBio, Inc. (IBIO)

NYSE American - Nasdaq Real Time Price. Currency in USD
1.1996+0.0196 (+1.66%)
At close: 03:59PM EST
1.2100 +0.01 (+0.87%)
After hours: 07:50PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.1800
Open1.2600
Bid1.1600 x 900
Ask1.2200 x 900
Day's Range1.1850 - 1.2265
52 Week Range1.0200 - 52.0000
Volume32,626
Avg. Volume190,918
Market Cap4.18M
Beta (5Y Monthly)-3.84
PE Ratio (TTM)N/A
EPS (TTM)-15.5000
Earnings DateMay 13, 2024 - May 17, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for IBIO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • iBio, Inc.
    Analyst Report: Johnson & JohnsonJohnson & Johnson is a diversified healthcare company that develops, manufactures and markets products in two business segments: Innovative Medicine (formerly Pharmaceuticals) and MedTech.
    Rating
    Fair Value
    Economic Moat
    29 days agoArgus Research
View more
  • GlobeNewswire

    iBio Announces Participation in 23rd Annual PepTalk Conference

    - VP of Platform Technologies, Matt Greving, to give podium presentation on enhancing bispecific T-cell engager discovery and development with machine learning -BRYAN, Texas and SAN DIEGO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today that Matthew P. Greving Ph.D., its Vice President and Head of Platform Technologies and Machine Learning, will give a podium presentation titled "En

  • GlobeNewswire

    iBio Amends and Extends Maturity of Credit Agreement

    – Extends maturity date to March 29, 2024 – – Allows for more time to complete planned divestiture of legacy CDMO business - BRYAN, Texas and SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced its wholly owned subsidiary, iBio CDMO LLC, and its lender, Woodforest National Bank (“Woodforest”), have entered into an amendment (the “Amendment”) to the Credit Agreement dated Nove

  • GlobeNewswire

    iBio, Inc. Announces Pricing of $4.5 Million Public Offering

    BRYAN, Texas and SAN DIEGO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), today announced the pricing of its reasonable best efforts public offering of 2,250,000 of its shares of common stock (or common stock equivalents in lieu thereof) and accompanying Series C and Series D warrants to purchase up to an aggregate of 2,250,000 shares of common stock at a combined public offering price of $2.00, resulting in gross proceeds of approximately $4.5 million. The